Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DC-853 by DICE Therapeutics for Inflammation: Likelihood of Approval
DC-853 is under clinical development by DICE Therapeutics and currently in Phase I for Inflammation. According to GlobalData, Phase I...
DC-853 by DICE Therapeutics for Autoimmune Disorders: Likelihood of Approval
DC-853 is under clinical development by DICE Therapeutics and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase...
DC-853 by DICE Therapeutics for Psoriasis: Likelihood of Approval
DC-853 is under clinical development by DICE Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase I...